Clinical Trial Update: Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus [Phase 1]

View source ↗

Summary

A Phase 1 safety study of AMG 557 in subjects with subacute cutaneous lupus erythematosus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• AMG 557

Snippet

Sponsor: Amgen | Conditions: Cutaneous Lupus, Lupus | Phase 1 | Status: TERMINATED